Benzinga | May 10, 2021 06:13AM EDT

HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $251

HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $255 to $251.